A phase 3, multicenter, open-label extension study of Zilucoplan in subjects with generalized myasthenia gravis (RA Pharma 302: Raise XT)

Study RA101495-02.302 is a multicenter, open-label extension study to evaluate the long-term efficacy, safety, and tolerability of zilucoplan in subjects with gMG who have previously participated in a qualifying Ra Pharmaceuticals sponsored zilucoplan study. The visit schedule during the first 12 weeks of Study RA101495-02.302 (RAISE)

UCB RA pharma
Principal Investigator(s)
Dr. Henry Kaminski
Contact Phone Number
Request Information

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

5 + 9 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.